WS #10796

From 500 msgs · 13 key-dev

Neuphoria Therapeutics confirms discussions with Scancell Holdings about potential acquisition; Scancell would become Nasdaq-listed. FDA issues Complete Response Letter for Lantheus' LNTH-2501 NDA due to third-party manufacturing issues; no safety/efficacy concerns.

Neuphoria-Scancell acquisition talks

Neuphoria Therapeutics confirms discussions with Scancell Holdings about potential acquisition; Scancell would become Nasdaq-listed.

FDA issues Complete Response Letter for Lantheus' LNTH-2501 NDA due to third-party manufacturing issues; no safety/efficacy concerns.

Full world state #10796 →